QC
MYGN icon

Quadrature Capital’s Myriad Genetics MYGN Stock Holding History

Quadrature Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Buy
44,165
+15,399
+54% +$69.9K ﹤0.01% 1272
2026
Q1 		$129K Buy
+28,766
New +$150K ﹤0.01% 1192

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadrature Capital's MYGN Position: Q2 2026 in Review

Quadrature Capital increased its Myriad Genetics (MYGN) stake by 54% in Q2 2026, buying an estimated $69.9K and bringing the position to 44,165 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #1272.

Quadrature Capital first reported a position in MYGN in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Quadrature Capital held 44,165 shares of Myriad Genetics worth $252K as of Q2 2026.
  • Quadrature Capital bought 15,399 Myriad Genetics shares in Q2 2026, an estimated $69.9K.
  • Myriad Genetics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1272 holding.
  • Quadrature Capital first reported a position in Myriad Genetics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.